Express News | Eli Lilly and Co will conduct research on whether weight loss drugs can effectively control addictive behavior.

Breakings21:10

Evotec And Novo Nordisk Launch First Projects For LAB EN2 Accelerator, Focusing On Cardiometabolic Diseases

Benzinga15:55

Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.

Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.

Zhitong Finance11:25

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking Alpha06:01

Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk

WSJDec 10 23:06

Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'

BenzingaDec 10 21:27